The treatment being tested combines Aspirin Protect (100 mg daily) and Folic Acid (5 mg daily). Some participants will receive these medications, while others will receive a placebo version of one or both medications. The study will track changes in hearing ability over time, particularly focusing on the improvement in hearing after 15 days of treatment.

Participants will be monitored for changes in their hearing through various tests over a period of 6 months. The study will measure hearing improvement, speech understanding, balance function, and quality of life. Regular check-ups will occur at specific intervals throughout the study period to assess how well the treatment is working.

The purpose of the study is to evaluate how well this treatment improves hearing in patients who have not responded to other treatments, such as oral or ear injections of steroids. Participants in the study will receive either the triamcinolone acetonide injection or a placebo. The study will observe changes in hearing ability over a period of time, using tests that measure how well participants can hear different tones and understand speech.

Throughout the study, participants will undergo various hearing tests, including the pure tone audiometry, which measures the ability to hear sounds at different pitches, and speech tests to assess how well they can understand spoken words. The study aims to provide insights into the effectiveness of this treatment for those with persistent hearing loss after other therapies have failed.

Participants in this study have previously received an injection of AAVAnc80-hOTOF directly into the cochlea, which is part of the inner ear. The study will monitor these individuals over an extended period to ensure the treatment remains safe and to observe any potential side effects. The study will also assess the effectiveness of the treatment in improving hearing through various tests, such as measuring hearing thresholds and speech recognition.

The study will involve regular check-ups, including physical exams and hearing tests, to track the participants’ health and hearing abilities. The goal is to gather comprehensive data on the safety and potential benefits of AAVAnc80-hOTOF for individuals with OTOF-related hearing loss.

Participants in the study will be adults who are receiving cisplatin as part of their cancer treatment. The study will involve taking SENS-401 at a dose of 43.5 mg twice a day for up to 23 weeks. The effectiveness of SENS-401 in preventing hearing loss will be assessed four weeks after the last dose of cisplatin. Some participants will receive a placebo instead of SENS-401 to compare the outcomes.

The study will monitor changes in hearing ability by measuring hearing thresholds, which are the quietest sounds a person can hear, at various frequencies. This will help determine if SENS-401 is effective in protecting against hearing loss. The trial is expected to continue until March 2025, with participants being recruited since December 2022.

The purpose of the study is to find the best dose of DB-OTO and to see how safe and well-tolerated it is in young patients. The study will start with a single injection in one ear and may later include injections in both ears. Participants will be monitored to see how they respond to the treatment and to check for any side effects. The study will also look at changes in hearing ability using tests that measure how well the brain responds to sound and how well participants can hear different tones and speech.

This trial is open-label, meaning that both the researchers and participants will know which treatment is being given. The study will take place over several years, allowing researchers to gather important information about the safety and effectiveness of DB-OTO in treating hearing loss due to OTOF mutations.

The purpose of the study is to evaluate the safety and effects of different doses of AAVAnc80-hOTOF in individuals with this specific type of hearing loss. Participants will receive the treatment through an injection into the cochlea, and the study will monitor their response over time. The trial will assess how well the treatment is tolerated and whether it has any impact on hearing ability.

Throughout the study, participants will undergo various tests, including auditory brainstem response (ABR) testing, to measure changes in their hearing. The study aims to gather information on any side effects related to the treatment and the procedure used to administer it. This research is expected to continue until 2028, providing valuable insights into the potential of gene therapy for treating hearing loss caused by OTOF mutations.

Participants in the study will receive injections directly into the ear, a method known as intratympanic injection. The study will compare the effects of methylprednisolone with those of a placebo over a period of one year. The goal is to see if the treatment can provide better control over vertigo attacks compared to not receiving the active medication. The study will also monitor the quality of life of participants, including aspects related to dizziness and tinnitus, which is a ringing or buzzing noise in one or both ears that may be associated with Menière’s disease.

In addition to methylprednisolone, the study will also consider the use of other medications such as dexamethasone, triamcinolone, and gentamicin, which are also administered through intratympanic injections. The study will track the frequency of these injections and assess their impact on hearing and overall well-being. The trial will also evaluate the use of metoclopramide, a medication that can help manage nausea and vomiting, which are common symptoms during vertigo attacks. The study is designed to provide valuable insights into the effectiveness and safety of these treatments for managing Menière’s disease.